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The past 20 years have seen many advances in our understanding of protein-protein interactions (PPIs) and
how to target themwith small-molecule therapeutics. In 2004, we reviewed some early successes; since then,
potent inhibitors have been developed for diverse protein complexes, and compounds are now in clinical
trials for six targets. Surprisingly, many of these PPI clinical candidates have efficiency metrics typical of
‘‘lead-like’’ or ‘‘drug-like’’ molecules and are orally available. Successful discovery efforts have integrated
multiple disciplines andmake use of all themodern tools of target-based discovery—structure, computation,
screening, and biomarkers. PPIs become progressively more challenging as the interfaces become more
complex, i.e., as binding epitopes are displayed on primary, secondary, or tertiary structures. Here, we review
the last 10 years of progress, focusing on the properties of PPI inhibitors that have advanced to clinical trials
and prospects for the future of PPI drug discovery.Protein-protein interactions (PPIs) represent a vast class of ther-
apeutic targets both inside and outside the cell. PPIs are central
to all biological processes and are often dysregulated in disease.
Despite the importance of PPIs in biology, this target class has
been extremely challenging to convert to therapeutics. Twenty
years ago, PPIs were deemed ‘‘intractable.’’ High-resolution
structures in the 1980s to 1990s showed that PPI interfaces
are generally flat and large (roughly 1,000–2,000 A2 per side)
(Hwang et al., 2010), in stark contrast to the deep cavities that
typically bind small molecules (300–500 A2) (Fuller et al.,
2009). Unlike enzymes or G protein-coupled receptors (GPCRs),
nature did not offer simple small molecules that can start a
chemical discovery process, and high-throughput screening
(HTS) had not provided validated hits.
Between 1995 and 2005, hopeful signs were emerging. A
clinically approved integrin antagonist (tirofiban) and natural
products like taxanes, rapamycin, and cyclosporine inspired
confidence that PPIs could be modulated by small molecules.
Mutational analysis of protein interfaces showed that not all res-
idues at the PPI interface were critical, but rather that small ‘‘hot
spots’’ conferred most of the binding energy (Arkin and Wells,
2004; Clackson and Wells, 1995). Hot spots tended to cluster
at the center of the interface, to cover an area comparable to
the size of a small molecule, to be hydrophobic, and to show
conformational adaptivity. These features suggested that at least
some PPIs might have small-molecule-sized patches that could
dynamically adjust to bind a drug-like molecule. By 2005, about
a half-dozen small molecules had been reported to bind with
the affinities one would expect for drug leads, at binding sites
defined by high-resolution structures (Wells and McClendon,
2007). In parallel, computation and chemical technologies were
being developed that might be well suited to PPIs. For instance,
fragment-based lead discovery (FBLD) has had a particularly
strong impact. FBLD used biophysical methods, including crys-
tallography, surface plasmon resonance, and nuclear magnetic
resonance (NMR), or disulfide trapping (tethering) to identify
low-molecular-weight, low-complexity molecules that bound1102 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltweakly to subsites on the protein surface (Erlanson et al., 2004;
Hajduk and Greer, 2007; Winter et al., 2012).
The last decade has seen amazing progress in tackling chal-
lenging PPI targets with synthetic molecules. More than 40
PPIs have now been targeted (Basse et al., 2013; Higueruelo
et al., 2009; Labbe´ et al., 2013), and several inhibitors have
reached clinical trials. With this advance, it is important to recon-
sider the distinction between ligandability (‘‘druggability’’) and
our ability to convert PPI inhibitors into drugs. Historically, PPI
inhibitors have been larger and more hydrophobic than
typical orally available drugs (Wells and McClendon, 2007).
Two commonly used metrics to assess the drug-like quality of
a compound (or to compare a series of compounds) are ligand
efficiency (LE; DG/HA) and lipophilic ligand efficiency (LLE;
pIC50 – logD or logP) (Hopkins et al., 2014). The LE for small-
molecule inhibitors of PPIs have hovered around 0.24, whereas
a LE of0.3 or higher is desired. Values of LLE >5 are considered
favorable for in vivo activity. Encouragingly, recent PPI inhibitors
are approaching these ‘‘drug-like’’ values for several targets (see
below). Even inhibitors with properties outside average ranges
for oral drugs have been made orally bioavailable. Clinically suc-
cessful PPI inhibitorsmay therefore expand our understanding of
the types of molecules that can be made into drugs.
Also during the past fifteen years, there has been very prom-
ising progress with designing peptides that target PPIs and
show promising cell-based (and even in vivo) activities (Azzarito
et al., 2013; Bernal et al., 2010; Boersma et al., 2012; Chang
et al., 2013; DeLano et al., 2000; Gavenonis et al., 2014). While
these approaches are outside the scope of the current review,
they represent a parallel strategy that can also inform small-
molecule design.
Although PPIs come in many shapes and sizes, most of the
clinical-stage inhibitors target PPIs in which the hot-spot resi-
dues are concentrated in small binding pockets (250–900 A2)
(Basse et al., 2013; Smith and Gestwicki, 2012) and partner
proteins are characterized by short primary sequences at the
interface (London et al., 2013; Perkins et al., 2010). At oned All rights reserved
Figure 1. The Complexity of the PPI Interface Affects Druggability
PPIs can be classified bywhether one side of the interface consists of a primary
(linear) protein sequence (green), a single region of secondary structure (such
as an alpha helix, yellow), or multiple sequences requiring tertiary structure
(red). There are fewer examples of small-molecule inhibitors of PPIs as the
interface becomes more complex (from primary, to secondary, to tertiary epi-
topes). Structures shown are BRDt/histone (green; Protein Data Bank [PDB]:
2WP1), MDM2/p53 (yellow; PDB: 1YCR), and IL-2/IL-2Ra (red; PDB: 1Z92).
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epitope 1–4 amino acids long; there are four clinical-stage exam-
ples of small-molecule mimetics of these epitopes. PPIs that
contain a single unit of secondary structure, such as an alpha he-
lix, binding to a hydrophobic groove have also proven tractable
to small-molecule inhibition. Globular interfaces, requiring ter-
tiary structure on both sides of the PPI, have fewer published
successes. In developing guidelines for PPI inhibitor discovery,
it is instructive to consider each clinical success story in the
context of the type of interface (Figure 1).
Primary Peptide Epitopes: Short, Continuous, Linear
Peptides
One of the first examples of a clinically successful PPI inhibitor is
tirofiban,whichbinds to the integrin IIbIIIa. Tirofibanwasdesigned
to mimic the linear tripeptide Arg-Gly-Asp (RGD), the epitope of
fibrinogen that binds to the ‘‘I-like’’ domain of IIbIIIa (Hartman
et al., 1992). While this small, linear peptide epitope seems like a
special case of PPI, this motif is observed in turns, at protein
termini, and in unstructured regions (Perkins et al., 2010). Unsur-
prisingly, these types of interfaces have been particularly
amenable to inhibition by small molecules, and four such targets
have recently entered clinical trials, which we discuss below.
LFA1
Leukocyte function-associated antigen-1 (LFA-1) has been the
target of drug discovery efforts aimed at reducing inflammatory
immune responses. LFA-1 is a beta2 integrin involved in T cell
activation and adhesion (Ford and Larsen, 2009) through binding
to its ligand ICAM1. LFA-1 is a heterodimer consisting of an alpha
chain (CD11a/aL) and a beta chain (CD18/b2). ICAM1 binds to an
inserted domain (I domain) located on CD11a. CD18 also has an
I-like domain that is located near the I domain. Three types of
drugs have been in the clinic for LFA-1. The anti-LFA-1 antibody
efalizumab was approved for psoriasis in 2003, but it was with-
drawn in 2009 due to rare but fatal viral infections associatedChemistry & Biology 2with immunosuppression (Schwab et al., 2012). Small molecules
that bound to an allosteric site on the I domain were in clinical
trials for psoriasis, but no development has been reported since
2010 (Guckian and Scott, 2013). Lifitegrast (SAR1118), however,
recently completed its registrational phase 3 trial, and a new
drug application will be filed in early 2015 (Shire, 2014).
Lifitegrast was discovered at Sunesis, building from a series
originally published by Genentech (Gadek et al., 2002), and
was developed clinically by SARcode/Shire (Zhong et al.,
2012). There are no crystal structures of lifitegrast or its analogs
bound to LFA-1. The mechanism of action of the compound is
still under debate; it either binds directly to the ICAM site on
the I domain (Keating et al., 2006) or to the related site on the
I-like domain (Shimaoka et al., 2003) (Figure 2), analogous to
the binding of tirofiban. SARcode developed lifitegrast for the in-
flammatory disorder dry eye syndrome, the most common eye
disease in humans (Schaumberg et al., 2003). SAR1118 has an
optimal pharmacokinetic profile for ocular formulation, with low
systemic exposure and high aqueous solubility. Since this indi-
cation does not require systemic exposure, lifitegrast could
achieve the efficacy that eluded I domain antagonists (Guckian
and Scott, 2013) and avoid the toxicity that led to efalizumab’s
withdrawal (Schwab et al., 2012).
IAPs
Inhibitor of apoptosis proteins (IAPs), including cIAP1, cIAP2,
and XIAP, are important regulators of cell fate, including
apoptotic cell death and immunity (Dubrez et al., 2013; Fulda
and Vucic, 2012). The IAPs have PPI interaction domains called
BIR domains and a RING domain E3 ubiquitin-ligase domain.
The BIRs bind directly to an N-terminal tetrapeptide sequence
exposed during proteolytic activation of caspase-3, caspase-7,
and caspase-9, thus inhibiting the activity of these proapoptotic
proteases. IAPs ubiquitin-ligase activity also leads to the ubiq-
uitylation and degradation of caspases (Dueber et al., 2011)
and other proteins involved in apoptosis and NF-kB signaling
(reviewed in Fulda and Vucic, 2012). Current thinking holds
that XIAP inhibition directly affects caspase activity, whereas
cIAP inhibition leads to stronger ubiquitin-mediated effects.
Development of homolog-selective inhibitors of the IAPs will
allow evaluation of these pathways in cancer therapy and toxicity
(Condon et al., 2014; Ndubaku et al., 2009; Sun et al., 2014).
An endogenous inhibitor of IAPs, called Smac (second mito-
chondrial activator of caspases), competeswith caspase binding
to BIR domains and thereby stimulates apoptosis (Liu et al.,
2000). Small-molecule IAP inhibitors mimic the tetrapeptide-
binding motif on Smac and are therefore called Smac mimetics
(SMs). The Smac peptide motif, Ala-Val-Pro-Ile (AVPI), binds to
two adjacent subpockets on BIR domains (Liu et al., 2000).
Hot-spot residues on the XIAP BIR3 domain focus on the pocket
that binds the N-terminal amine (E314) and alanine residue (L307
and W310) and W323, which interacts with proline. Smac pep-
tides are impressively tight binders; AVPI-amide binds cIAP1
with a Kd value of 2 nM (Condon et al., 2014). Since the first pep-
tidomimetic inhibitor of the IAP/Smac (and IAP/caspase) interac-
tion was disclosed (Oost et al., 2004), several groups have devel-
oped inhibitors with improved potency, PK, and in vivo activity.
These compounds mimic the key interactions between AVPI
and BIR domains (Figure 2). Seven SMs have reached clinical tri-
als, and five compounds remain active in clinical development.1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1103
Figure 2. Peptide-like Inhibitors of PPIs
with Primary Epitopes
(A) SAR1118 (lifitegrast) inhibits binding of LFA1
(CD11a/CD18) to its ligand ICAM. The mechanism
either involves binding directly to the ICAM site in
the I domain of CD11a (Keating et al., 2006) or
allosteric inhibition through binding to the I-like
domain in CD18 (Shimaoka et al., 2003).
(B) X-ray structure of a cIAP1/XIAP chimera (white
surface) bound to GDC-0152 (green sticks; PDB:
3UW4) and overlaid with SMAC peptide (magenta
cartoon; PDB: 1G73). Chemical structures of
SMAC mimetics in clinical trials are shown.
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monovalent antagonists, LCL161 (Novartis) (Dubrez et al.,
2013), GDC-0917/CUDC-427 (Genentech/Curis) (Flygare et al.,
2012; Wong et al., 2013) and SM-406/AT-406 (Wang lab/
Ascenta) (Cai et al., 2011) were designed from the AVPI peptide
and have IC50 values in the 2–60 nM range and a LE of0.3 (LLEs
are in the drug-like range of 6–7.5). The bivalent antagonists,
birinapant (TetraLogic) (Benetatos et al., 2014; Condon et al.,
2014) and SM-1387 (Bai et al., 2014), are dimerized SMs, de-
signed based on the idea that the Smac homodimer simulta-
neously binds to XIAP’s BIR2 and BIR3 domains (Huang et al.,
2003). These dimers demonstrate better cellular potencies
than their monovalent analogs. Unlike the orally active, monova-
lent compounds, the bivalent drug candidates are dosed intrave-
nously. SM-406 and birinapant bind 50-fold more tightly to
cIAP1 than XIAP and may allow clinical evaluation of whether
XIAP inhibition is required for efficacy.
Identifying patients who will respond to IAP inhibitors as single
agents has been challenging. SMs induce apoptosis in 15% of
cancer cell lines (Oost et al., 2004), suggesting that single-agent
activity of clinical compounds could be unpredictable. Transcrip-
tion profiling and genetic data suggest that certain tumor types
might be more sensitive, particularly MALT lymphomas with
constitutively active IAP protein fusions (Fulda and Vucic, 2012).
Importantly, preclinical and clinical studies have identified serum
cytokines and cIAP levels as potential biomarkers of response
(Dubrez et al., 2013), which could be used to quickly assess
whether a patient is resistant to SM treatment. Furthermore, pre-
clinical data provides a strong rationale for several combinations
with radiation and chemotherapeutics, including the apoptotic
agonist TRAIL (Fulda and Vucic, 2012). The preclinical data also1104 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltd All rights reservedpoint to the potential for on-target toxic-
ities (Erickson et al., 2013; Yang and
Novack, 2013). To date, clinical trials are
too early to assess anticancer activity,
but the clinical compounds appear to
behave well and are tolerated at doses
that show strong pharmacodynamic ef-
fects (Infante et al., 2014; A.W. Tolcher
et al., 2013, J. Clin. Oncol., abstract).
Bromodomains
The cellular decision to transcribe a gene
requires the complex integration of signal
transduction, the action of DNA-binding
proteins that repress or stimulate tran-scription, and epigenetic signals on the DNA and DNA-bound
histones. Transcriptional complexes are highly dynamic and
contain multiple enzymes, scaffolding proteins, and DNA-bind-
ing proteins (Lessard and Crabtree, 2010). These complexes
represent multiple opportunities to activate or repress transcrip-
tion using small-molecule modulators of PPIs.
Bromodomains are epigenetic ‘‘readers’’ that recognize acet-
ylated lysines (Kacs) on histone tails and direct transcription
complexes to turn on genes (Filippakopoulos and Knapp,
2014). Bromodomains share a conserved hydrophobic pocket
formed by a left-handed four-helical bundle and loop regions
of various lengths and charges. An asparagine residue and five
ordered water molecules recognize Kac-histone peptides with
100 mM affinity (Vollmuth et al., 2009). This deep pocket has
been exploited by synthetic Kac mimetics that bind with much
higher affinity than the native peptide. One of the first published
examples, (+)-JQ1, stimulated strong interest in bromodomain-
containing protein 4 (BRD4) as a cancer target and in the drugg-
ability of bromodomains as a class (Filippakopoulos et al., 2010;
Vidler et al., 2012). (+)-JQ1 binds to BRD4 with an affinity of
49 nM. Crystal structures show that (+)-JQ1 completely oc-
cupies the acetyl-lysine binding groove, including hydrophobic
interactions not seen in the histone H3 peptide/BRD4 complex
(Figure 3). In the past 5 years, several potent inhibitors have
been described and have been used to explore the biology of
bromodomains in cancer and inflammation (reviewed in Filippa-
kopoulos and Knapp, 2014).
Five compounds have already advanced to clinical trials.
I-BET762 (Glaxo Smith-Klein) (Mirguet et al., 2013), CPI-0610
(Constellation) (Gehling et al., 2013), Ten-010 (Tensha) (Rohn,
2012), and OTX15 (OncEthix) (P. Herait et al., 2014, Am. Assoc.
Figure 3. Small-Molecule Inhibitors of PPIs
with Primary Epitopes
(A) Crystal structure of BRD4 bromodomain (white
surface) bound to (+)-JQ1 (green sticks; PDB:
3MXF) overlaid with acetylated histone peptide
(magenta cartoon; PDB: 2WP1). Clinical com-
pounds or their closest published analogs are
shown below.
(B) Crystal structure of the dimerization interface of
HIV integrase (white and cyan surface) bound to
compound 16 (green sticks; PDB: 4NYF) with
overlaid epitope from LEDGF (magenta; PDB:
2B4J). Compound 16 is a precursor to the clinical
compound BI 224436.
(C) Von-Hippel Lindau (VHL) protein (white sur-
face) with bound inhibitor compound 51 (green
sticks; PDB: 4B9K). The central hydroxyproline
mimics the binding of a peptide derived from
HIF1a (PDB: 4AJY; not shown).
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(Figure 3) and are in clinical trials for cancer, including NUT
midline carcinoma, a rare cancer caused by BRD4-NUT fusions
(Filippakopoulos et al., 2010). RVX-208 is a quinazolinone that
binds deeply into the Kac pocket, making a hydrogen bond
to the Kac-recognizing asparagine residue; unlike the JQ1-like
compounds, it binds preferentially to the second bromodomain
of BRD3 (McLure et al., 2013). RVX-208 has been in phase 2
trials for atherosclerosis, with promising results. The clinical
compounds were identified through a range of methods. For
instance, I-BET762 and RVX-208 were found in cell-based HTS
focused on ApoA1 upregulation (for atherosclerosis) and were
later found to bind BET bromodomains (McLure et al., 2013; Mir-
guet et al., 2013); compound 3, a published analog of CPI-0610,
was evolved from an isoxazole fragment merged with the core
structure of JQ1 (Gehling et al., 2013). BET proteins may repre-
sent a best-case scenario for PPI inhibition, since the primary
recognition element is a single amino acid. However, the ability
to develop potent, ligand-efficient (average LE = 0.34; Table 1)Chemistry & Biology 21, September 18, 2014 ªinhibitors, even though histone peptides
bind with low affinity, speaks to the po-
tential to gain binding energy that is not
used by the native PPI.
HIV Integrase
Viruses hijack host proteins to facilitate
their replication and survival; these host/
pathogen complexes represent impor-
tant clinical targets. The homotetrameric
protein HIV integrase (IN) integrates the
viral genome into human DNA by cata-
lyzing 30 processing and strand transfer.
The HIV drugs raltegravir and elvitegravir
bind to the active site of IN and inhibit its
enzymatic activity. Recently, a second
class of IN inhibitors targeting a host/
pathogen PPI have reached the clinic
(Engelman et al., 2013).
The human protein lens endothelial
growth factor (LEDGF) acts as an IN
cofactor, facilitating integration of the viral
genome into the host chromosome, pro-tecting IN from proteolytic degradation, and stimulating its
catalytic activity (Engelman et al., 2013). The cocrystal structure
of LEDGF binding domain with a dimer of IN catalytic domain
shows a short turn of helix from LEDGF pointing into the IN
dimer interface, with 400 A2 buried surface area on IN
(Cherepanov et al., 2005; Basse et al., 2013). LEDGF-mimicking
peptides provided a proof of concept for inhibiting the LEDGF/
IN PPI, and stimulated small-molecule discovery programs
based on virtual screening, structure-aided design, and HTS (re-
viewed inDe Luca et al., 2011). Themost potent PPI inhibitors are
tert-Butoxy-(4-phenyl-quinolin-3-yl)-acetic acid (tBPQA) deriva-
tives (Figure 3), including the clinical compound BI-224436
(Boehringer-Ingelheim, Gilead), which has low nanomolar anti-
viral potency, LE = 0.33, and LLE = 11.5 (Table 1) (Fader et al.,
2014; Fenwick et al., 2014). tBPQAs were found in an HTS de-
signed to identify inhibitors of IN-catalyzed 30 processing of
DNA; structural studies later revealed the compound bound to
LEDGF binding pocket at the IN dimer interface. The quinolone
core positions the two side-chain mimetics; as with BRD42014 Elsevier Ltd All rights reserved 1105
Table 1. Properties of Selected Protein-Protein Interaction Inhibitors
PPI Target/Partnera Compound Name MW (Da) IC50 (nM) LE
b LLEc Oral Bioavailability
Primary Epitope
LFA1/ICAM1 SAR1118 (lifitegrast) 615 9 0.27 4.8 
cIAP/SMAC GDC-0152 499 14 0.31 6.3 
GDC-0917/CUDC-427 565 50d 0.22 6.0 +
AT-406/SM-406 562 2 0.30 7.5 +
TL-32711 (birinapant) 809 1 0.22 11.4 
Bromodomain/histone I-BET762 (GSK 525762) 424 630 0.29 2.9 +
compound 3e 400 26 0.39 3.5 +
RVX-208 370 200 0.35 3.8 nd
Integrase/LEDGF BI 224436 443 20 0.33 11.5 +
VHL/HIF1a compound 51 450 900 0.26 4.4 nd
Secondary Epitope
BCL family/BH3 ABT-263 (navitoclax) 975 0.40 0.21 1.2 +
ABT-199 868 0.01 0.24 3.1 +
compound 14 437 10 0.37 3.3 +
MDM2/p53 RG7112 (Ro5045337) 728 18 0.23 0.7 +
RG7388 (Ro5503781) 616 6 0.27 4.3 +
MI-888f 548 0.44 0.35 6.7 +
PDK1/PIF-tide PS210 380 3,000 0.32 4.5 nd
Menin/MLL MIV-6R 418 85 0.32 4.1 nd
MIV-2-2 416 20 0.45 3.6 nd
p300 CH1 domain/HIF1a OHM 1 495 500 0.27 6.8 nd
Tertiary Epitope
IL-2/IL-2Ra SP4206 663 60 0.22 4.6 nd
HPV11 E1/E2 BILH 434 608 40 0.25 2.3 nd
MW, molecular weight; nd, not determined.
aItalicized compounds are in active clinical development. For PPI families (e.g., BCL family/BH3, bromodomains, and IAPs), the highest affinity/lowest
IC50 is reported. When available, Kd values are reported.
bLE = DG / number of heavy atoms.
cLLE = pIC50 – clogD.
dActivity is <60 nM (Wong et al., 2013).
eCompound 3 is an analog of the undisclosed clinical compound CPI-0610.
fMI-888 is an analog of the undisclosed clinical compound MI-773.
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not (Figure 3).
tBPQAs are dual inhibitors. In addition to inhibiting the LEDGF/
IN complex, they also allosterically inhibit IN catalytic activity
by preventing the formation of functional IN tetramer. Recent
studies suggest that the mechanism of these inhibitors is com-
plex and altering tetramerization may be more therapeutically
important than inhibiting LEDGF per se (Balakrishnan et al.,
2013; Sharma et al., 2014). BI-224436 could provide a new
mechanism for HIV treatment that will most likely have a different
resistance profile than active site IN inhibitors. Furthermore, its
story highlights the fact that enzyme/protein complexes have
multiple effects on the enzyme; small-molecule inhibitors might
alter one or more of these functions.
Prospects for Primary Sequence Epitopes
Inhibitors of PPIs that consist of primary sequence epitopes have
been discovered using multiple approaches. Fragment-based,
biochemical, and cell-based screening have all yielded hits for
this PPI class (Fader et al., 2014; Gehling et al., 2013; Mirguet1106 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltet al., 2013). The success of screening for primary-epitope
PPIs is consistent with the theory of Hann et al., which posits
that less complex interfaces are more likely to yield to
diversity-based screening (Hann et al., 2001). Design strategies
based on the peptide epitope are also logical, since the native
ligand is close to the size of a drug-sized inhibitor. Such
epitope-mimetic design was recently demonstrated for the
HIF1a/the von Hippel-Lindau protein (VHL) interaction (Buckley
et al., 2012a; Buckley et al., 2012b). Similar to BRD4, HIF1a
recognition focuses on a single, modified amino acid. Here,
Crews and coworkers virtually screened a library of com-
pounds to mimic a tripeptide epitope on VHL that centers on
hydroxyproline. They identified an oxazole-hydroxyproline scaf-
fold, optimized the compound to arrive at a 1 mM inhibitor of
the PPI, and showed by crystallography that these compounds
bind at the hydroxyproline site. Finally, since inhibitors are
either peptidic or compact, LE and LLE values tend to be high.
Hence, both the variety of discovery strategies and the chemical
properties of hits are favorable for PPIs with linear epitopes.d All rights reserved
Figure 4. BCL-2/BCL-xL and MDM2
Interfaces Contain Secondary Epitopes
(A) Structure of BCL-2 (white surface) bound to
ABT-199 (green sticks; PDB: 4MAN) with overlaid
BAX BH3 peptide (magenta cartoon; PBD: 2XA0).
Chemical structures of selected BCL-2 and BCL-
xL inhibitors are shown.
(B) Structure of MDM2 (white surface) bound
to RG7112 (green sticks; PDB: 4IPF) with over-
laid p53 peptide (magenta cartoon; PDB: 1YCR).
Chemical structures of compounds in clinical
testing or their closest published analogs are
shown.
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Extended Peptides
It has been estimated that up to 40% of PPIs consist of a single
peptide from one protein that binds into a groove on the other
(Petsalaki and Russell, 2008). Sixty percent of PPI in the protein
databank utilize an a helix, and 60%of these bind a single face of
the helix (Raj et al., 2013). In general, hot spots on the target pro-
tein are centered on two to three subpockets that bind hydro-
phobic residues on the partner peptide. Such interfaces have
been described as ‘‘hot sequences’’ (London et al., 2010) or
‘‘secondary-structural epitopes,’’ reflecting the fact that the
key residues on the peptide are not next to each other in the pri-
mary sequence, but that an isolated peptide can often mimic the
binding affinity and pose of the PPI.
BCL Family
BCL family proteins are central effectors of apoptosis. Proapo-
ptotic family members, including BAD and BAK, are kept in an
inhibited state through binding to the antiapoptotic family mem-
bers, including BCL-2, BCL-xL, and MCL1. The antiapoptotic
members are helical proteins with an open groove that binds
to a single helix (the BH3 domain) on the proapoptotic partner.
Upregulation of the antiapoptotic BCL family members is an
important mechanism through which cancer cells avoid cell
death in the face of pathway dysregulation, radiation, and
chemotherapy. The structure of BCL-xL bound to BAK peptide
(16-mer, Kd = 340 nM) suggested that this PPI might be particu-
larly druggable (Sattler et al., 1997). The binding site onBCL-xL is
comprised of two large (200 A2) nearby pockets and three hy-
drophobic residues from the BH3 peptides define the PPI hot
spot (Oltersdorf et al., 2005). Indeed, between 2000 and 2004,
several laboratories published small-molecule inhibitors withChemistry & Biology 21, September 18, 2014 ªpotencies in the 0.1–10 mM range that
bound in the BAK-binding site (reviewed
in Arkin and Wells, 2004).
The major preclinical breakthrough
was the 2005 disclosure of ABT-737,
which was discovered through NMR-
based fragment discovery, structure-
based design, and medicinal chemistry
(Oltersdorf et al., 2005). ABT-737 binds
to BCL-2, BCL-xL, and BCL-W with sub-
nanomolar affinity, but it is also a large
compound (MW = 813 Da), with LE =
0.21. ABT-737 demonstrated impressive
single-agent activity in cancer xenograft
models, but was not orally bioavailable(Oltersdorf et al., 2005). In 2008, Abbott disclosed the orally
available analog ABT-263 (Tse et al., 2008), which entered phase
1 and 2 clinical trials for solid tumors and chronic lymphocytic
leukemia (CLL) (Roberts et al., 2012; Rudin et al., 2012). During
these early clinical trials, thrombocytopenia (platelet loss) was
an important dose-limiting toxicity linked to BCL-xL inhibition.
Current clinical BCL family inhibitors are selective for BCL-2 or
BCL-xL. ABT-199 was designed to be selective toward BCL-2 to
avoid thrombocytopenia (Souers et al., 2013). To engineer selec-
tivity into ABT-263, a stripped-down scaffold was cocrystalized
with BCL-2. A tryptophan residue from a neighboring BCL-2
molecule sat very nearby to the inhibitor; linking of an indole at
that position led to ABT-199, which binds BCL-2 10-fold more
tightly than ABT-263 and shows 5,000-fold selectivity for BCL-2
compared to BCL-xL. Like its precursors, ABT-199 accesses
the BAK-binding pockets, but does not mimic the peptide back-
bone structure or side-chain orientation (Figure 4). ABT-199 is
currently in phase 1 trials for CLL, and preliminary results look
very promising, with response rates of >80% (Cancer Discovery,
2014). BCL-xL-selective inhibitors (e.g., compound 14; Figure 4)
have also been developed, with the aim of treating solid tumors
while avoiding the lymphocytic effects of BCL-2 (Koehler et al.,
2014). The L-shaped BCL-xL-selective series has a distinct bind-
ingmode fromABT-199 and appears to be buriedmore deeply in
the peptide-binding groove. It is noteworthy that both ABT-199
and compound 14 are more ligand efficient and have better LLE
than ABT-737 and ABT-263 (Table 1). Interestingly, cell-based
activity for BCL family inhibitors is generally 100- to 1,000-fold
weaker thanbindingaffinity. Thismaybedue topermeability, pro-
teinbinding,or thecellular context ofBCL-2-xLandseems tohold
for several members of this target class. Thus, very-high-affinity2014 Elsevier Ltd All rights reserved 1107
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still early days in the clinical life of BCL family antagonists, the
impressive story of their discovery highlights the realities of drug
discovery for a novel and challenging target; often, several itera-
tions of clinical candidates are needed to strike the ideal balance
of efficacy, safety, and dosing regimen.
MDM2
The transcription factor p53 is a master tumor suppressor that
regulates cell-fate decisions such as senescence, cell-cycle
arrest, and apoptosis. p53 or its regulators are mutated or
altered in most cancers, resulting in reduction or loss of p53
function. The ubiquitin E3 ligase responsible for p53 degradation
is MDM2 (murine double minute 2) and the MDM2/MDMx heter-
odimer (Khoo et al., 2014). This system is overexpressed or
amplified in several cancers with wild-type p53, and inhibition
of p53 ubiquitylation by MDM2 should lead to increased p53
levels and activity. The MDM2/p53 complex can be minimized
to an a helix from the N-terminal transactivation domain of p53
that binds into a pocket on the surface of the N-terminal domain
of MDM2 (Kussie et al., 1996). The MDM2/p53 interface is more
compact than that found for BCL-xL/BH3 peptide: the helix is
only two turns, and the three critical hot-spot residues (Phe19,
Trp23, and Leu26) point toward a deep pocket in the center of
the peptide-binding groove. The isolated peptide binds with
500 nM affinity to the N domain of MDM2.
The breakthrough for inhibiting p53/MDM2 came from the dis-
covery of the Nutlins, identified in a large high-throughput screen
(Vassilev et al., 2004). The optimized,100 nM inhibitor contains
a central imidazole ring with four substitutions. Three hydropho-
bic substitutionsmimic the binding of the three key residues from
p53, and the fourth substituent binds on the protein surface.
Soon after the discovery of the Nutlins, several labs described
compounds with different cores but similar molecular-recogni-
tion features (Fry, 2012; Khoo et al., 2014). A general feature is
a tripod shape that pushes at least two hydrophobic elements
deep into the binding site; these are fairly rigid structures that
use a central ring to enforce the side-chain geometries. Some
compounds also bind further along the p53-binding groove.
Compounds also differ in their ability to bindMDMX, whichmight
be important for efficacy and overcoming resistance in some
contexts (Khoo et al., 2014). The key observation from these
diverse MDM2 ligands is that many different scaffolds (including
peptides) can direct the hydrophobic groups into the p53-bind-
ing pocket. (Fry, 2012). Thus, it is not critical to mimic precisely
the peptide backbone or the peptide’s side-chain orientation.
One of the puzzling aspects ofMDM2 inhibitor design has been
the role of the fourth substituent. Modifications to this group alter
the compounds’ physicochemical characteristics and have a
modest effect on binding to the N-terminal domain of MDM2.
However, changes often have a disproportionate effect on cell-
based potency (Ding et al., 2013; Zhao et al., 2013). Recent
data suggest that parts ofMDM2outside thep53-bindingdomain
may play a role in the binding interaction. For instance, MDM2
mutations that render cells resistant to Nutlins often occur
outside the p53-binding domain (Wei et al., 2013). The direct
demonstration of a structural interaction has yet to be made,
but thegeneral point rings true: inminimizing thePPI for biochem-
ical and structural studies, we are likely to miss long-range inter-
actions that the compounds will face when they enter the cell.1108 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier LtThree scaffolds have been developed into experimental thera-
peutics. Roche initially took RG7112 (Figure 4) into phase 1 trials
(Tovar et al., 2013) and is currently testing the more potent and
ligand-efficient analog RG7388 (Ding et al., 2013). The spirooxin-
dole class of compounds, exemplified by MI-888, was discov-
eredby theWang lab atUniversity ofMichigan and is beingdevel-
oped by Sanofi (MI-773, structure not disclosed) (Zhao et al.,
2013). Roche recently disclosed Ro8994, a 5 nM (95% bioavail-
able) analog based on a spiroindolinone scaffold that combines
features of RG7388 andMI-888 (Zhang et al., 2014). Finally, Daii-
chi Sankyo is developing an undisclosed MDM2 inhibitor based
on a dihydroimidazothiazole scaffold (Miyazaki et al., 2013).
These clinical-stage inhibitors show impressive tumor regres-
sions in xenograft models and selective killing of cells containing
wild-type p53 versus those with mutant p53 (Tovar et al., 2013).
Their drug-like properties are also promising, with LE in the range
of 0.27–0.35, LLE in the range of 4.3–6.7, and very high oral bio-
availabilities despite molecular weights in the range of 550–730.
MDM2 inhibitors are being developed for single-agent use and
in combination with existing drugs. Early trials for RG7112 have
shown pharmacodynamic activity, including 3- to 5-fold in-
creases in levels of p53 and p53 target genes (Ray-Coquard
et al., 2012), and potential therapeutic activity in acute leukemia
(M. Andreeff et al., 2012, Am. Soc. Hematol., conference). The
biological challenges facing clinical positioning of these com-
pounds has been recently discussed (Khoo et al., 2014). Despite
decades of work on p53, its precise roles in survival and death
pathways remain to be elucidated; these clinical MDM2 antago-
nists are poised to address some of these critical issues.
Selected Emerging Examples of Secondary Structure
Epitope Inhibitors
Diverse methods have been used to develop secondary struc-
tural mimetics and prospects for developing inhibitors of this
class of PPI are good. One instructive example is the N lobe of
the kinase PDK1. This site binds to a 10-residue peptide called
a PDK1-interacting fragment (PIF-tide) from substrate proteins.
Binding serves to colocalize the proteins and to allosterically acti-
vate PDK1 kinase activity (Gold et al., 2006). Fragments that
mimic thePIF-tide havebeen found throughvirtual screening (En-
gel et al., 2006), NMR (Stockman et al., 2009), and tethering
(Sadowsky et al., 2011). For tethering, six cysteine residues
were introduced around the PIF-tide binding site and were
screened for binding to a library of disulfide-containing frag-
ments. Remarkably, fragments tethered at the same cysteine
residues could be either activators or inhibitors of PDK-1 kinase
activity. Cocrystal structures showed that activators pushed
the C helix toward the active site and better organized the cata-
lytic apparatus, whereas inhibitors shifted the C helix outward
into a less competent state (Figure 5). Thus, small changes in
the small-molecule ligand can have positive or negative effects
onenzymeallostery. Virtual screening, followedbychemical opti-
mization, provided cell active inhibitors of the PDK1/PIF-tide
interaction. PS210 (LE=0.35)mimics two hot-spot phenylalanine
residues on the PIF-tide (Busschots et al., 2012). In biochemical
assays, this compound activates the kinase toward peptide sub-
strates, asdoes thePIF-tide. Paradoxically, in cells, a cell-perme-
able version of PS210 inhibits phosphorylation of the subset of
PDK1 substrates that require binding at the PIF-tide site. We
recently identified cell active compounds from an HTS thatd All rights reserved
Figure 5. Preclinical Examples of Inhibitors
of PPIs with Secondary Epitopes
(A) Crystal structures of PDK-1, showing the PIF-
tide binding site bound with Tethered activator
(JS30, green sticks; PDB: 3OTU) or inhibitor (1F8,
magenta sticks; PDB: 3ORX). JS30 pushes the C
helix into a catalytically competent conformation.
The chemical structure of noncovalent PIF-tide
inhibitor PS210 is shown.
(B) Crystal structure of menin (white surface)
shown bound to MIV-6R (green sticks; PDB:
4OG8) with MLL peptide overlaid (magenta
cartoon; PDB: 3U85). Structures of MLL inhibitors
MIV-6R and MIV 2-2 are shown.
(C) Structure of OHM 1, which binds to CBP at the
HIF1a peptide-binding site.
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data). These compounds serveas additional examples of peptide
mimicry by small molecules and provide ligand efficient scaffolds
that may be further optimized.
Multiple approaches have also led to inhibitors of the transcrip-
tion factor mixed-lineage leukemia (MLL) protein at two different
domains. MLL binds to the scaffolding protein menin, and this
interfacecanbeminimized toan11-merpeptide from theN-termi-
nal domain ofMLL.HTS followedby structural biology andmedic-
inal chemistry led to MIV2-2 and MIV-6, potent, ligand-efficient,
and cell-active inhibitors that closely mimic the MLL peptide hot
spots (Figure 5 and Table 1) (He et al., 2014; Shi et al., 2012).
MLLalsobinds to theKIXdomainof theacetyltransferaseCBPus-
ing an a helix in the C-terminal domain of MLL. Mapp and
colleagues have designed synthetic molecules that bind to the
KIX domain at the MLL site (Buhrlage et al., 2009). They have
also used tethering to identify disulfide-bound compounds that
bind in the MLL site and allowed the first X-ray structure of the
KIX domain (Wang et al., 2013b). Their ultimate goal is to develop
bifunctional molecules that activate transcription by bringing
together DNA-binding proteins and transcriptional coactivators.
Prospects for Secondary Structure Epitope Design
Design approaches have focused on both the binding pocket
and the partner peptide. When focusing on the binding pocket,Chemistry & Biology 21, September 18, 2014 ªvirtual methods should allow for side-
chain flexibility, since hot spots at these
interfaces often show small motions that
create deeper binding pockets (Johnson
and Karanicolas, 2013; Wells and
McClendon, 2007). Pocket-based design
is justified by the observation that inhibi-
tors such as ABT-199 and RG7112 mimic
the function of hot-spot residues but
rarely mimic trajectories seen in the pep-
tide structures. Others have focused on
strategies to mimic the peptide partner
directly. For example, Lao et al. designed
an a-helical mimetic of the HIF1a transac-
tivation domain that binds to the cysteine-
histidine rich 1 (CH1) domain on CBP/
p300. The optimized compound OHM 1
is based on a bis-oxopiperazine scaffold;
OHM 1 binds CH1 with a Kd of 500 nM(Figure 5 and Table 1), downregulates hypoxia-inducible genes,
and inhibits tumor growth in a xenograft model (Lao et al., 2014).
Computational approaches to systematically replace peptide
residues have also seen some promising success (Guo et al.,
2014). This type of epitope is also highly amenable to stabilized
peptide approaches (Azzarito et al., 2013; Bernal et al., 2010;
Boersma et al., 2012; Chang et al., 2013). Historically, inhibitors
of PPIs with secondary-structural epitopes were large and had
low LE; however, the second-generation clinical compounds
and the PDK1, menin, and HIF1a lead compounds all fall into
more favorable ranges for LE and LLE.
Tertiary Structural Epitopes: Discontinuous
Binding Sites
Interleukin-17
The larger, shallower interfaces that originally discouraged drug
discovery remain challenging. Recently, Ensemble Therapeutics
disclosed the development of a macrocyclic compound that in-
hibits binding of interleukin-17 (IL-17) to its receptor (Livingston
et al., 2012), which represents a breakthrough in targeting
hormone/receptor interfaces with synthetic macrocyles. The
undisclosed structure has 3 nM affinity, a MW of 750 Da, and
a LE of 0.24. We eagerly await publication of the structural
and preclinical data surrounding this program.2014 Elsevier Ltd All rights reserved 1109
Figure 6. Small-Molecule Inhibitors of PPIs
with Tertiary Epitopes
(A) Structure of IL-2 (white surface) bound to
SP4206 (green sticks; PDB: 1PY2).
(B) Structure of transactivation domain of E2 pro-
tein fromHPV11 (white surface) bound to BILH 434
(green sticks; PDB: 1R6N).
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Two examples of PPI inhibitors highlight the dynamic nature
of globular PPIs. A series of compounds, exemplified by
SP4206, binds to IL-2 at the receptor-alpha interface (Figure 6)
(reviewed in Wilson and Arkin, 2011). These compounds were
identified serendipitously and optimized through fragment-
based methods, including tethering. IL-2 presents a relatively
flat surface in the apo- and IL-2Ra bound states but shows
pockets upon binding SP4206. SP4206 binds at the receptor-
binding hot spot and mimics the receptor’s hot-spot residues
and charge distribution, even though the residues on are sepa-
rated over multiple regions of the receptor’s structure. The
conformational changes seen across the SP4206-binding sur-
face include side-chain rotations and loop rearrangements,
larger changes than those observed for the peptide epitopes
described above. Molecular dynamics simulations suggest that
these structural adaptations are better thought of as part of the
protein conformational ensemble rather than induced fits.
BILH 434 (Figure 6) is another example of an inhibitor of a ter-
tiary structural epitope (Wang et al., 2004). Human papilloma
virus-11 (HPV11) requires the replication initiation factor E1 heli-
case to bind to the E2 transcription factor at specific DNA sites.
BILH 434 was identified in a screen for inhibitors of the E1/E2/
DNA complex and binds to the transactivation domain (TAD) of
E2 protein with a Kd of 40 nM (LE = 0.25). The X-ray structure
of the compound/E2 complex shows the compound nestled
into the elbow of the E2 TAD. Several side chains in this protein
interface change conformations to create a deep pocket for BILH
434 to bind. Again, changes to the structure were unanticipated
and were crucial for creating a binding site at an otherwise flat
surface. Importantly, both the IL-2 and E2 TAD discoveries relied
heavily on biophysical validation of the binding mode that was
confirmed by X-ray crystallography.
Prospects for Tertiary Epitope Binders
This class is probably the most challenging, and there are only
a handful of successful programs that have broken into the nano-
molar level of potency with modest LEs (typically 0.24 kcal/HA).1110 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltd All rights reservedThese interfaces tend to be much more
dynamic than the primary and secondary
class epitopes and thus less amenable
to virtual screening. Small molecules
can, however, find deeper pockets in
these interfaces and thus bind with higher
LE than their protein partner counterpart.
The small molecules also bind hot spots
predicted from alanine scanning. This
class is probably themost prevalent class
for extracellular PPIs. Strong validation
of the biology will certainly make this
class tempting—if high-hanging—fruit.For example, four groups have recently reported allosteric and
orthosteric PPI inhibitors of Ras, a very challenging cancer target
with no apparent deep pockets in the interface. Interestingly,
three groups took fragment-based approaches, using NMR
(Maurer et al., 2012; Sun et al., 2012) and tethering (Ostrem
et al., 2013), and one group identified inhibitors through virtual
screening (Shima et al., 2013). Finally, PPI-binding peptides
discovered from phage display could provide another avenue
toward peptide-based therapies (DeLano et al., 2000).
Allosteric Mechanisms of Inhibition
Functional screening for PPI inhibitors has also serendipi-
tously led to allosteric mechanisms of inhibition. For instance,
BIO8898, an inhibitor of the trimeric ligand CD40L, alters the
conformation of the trimer, thus inhibiting its binding toCD40 (Sil-
vianet al., 2011). Similarly, compoundshavebeen found that bind
and disrupt trimer formation for TNF (He et al., 2005). For multi-
component complexes, one way to harness this serendipity is
‘‘gray box’’ screening, where the protein network is assembled
in vitro. This approach has yielded interesting modulators of the
HSP70 chaperone network. Depending on the biological context
and how these HSP70 modulators bind, they have opposite
effects on folding and thus utility in different disease states (Li
et al., 2013; Wang et al., 2013a). Directed (as opposed to seren-
dipitous) allosteric modulation of PPIs provides potential way
forward for the most difficult targets (Nussinov and Tsai, 2014).
How Has Our Understanding of PPIs Evolved in the Past
10 Years?
The discovery of small, drug-like molecules that inhibit PPIs con-
tinues to be challenging, but the diverse success stories demon-
strate that it is possible for some systems. General strategies are
being sought, but it is likely that PPI is not properly thought of as
a target class analogous to class I GPCRs or kinases. PPIs are
extremely diverse in the size and shapes of the interfaces and
the binding affinities and dynamics of assembly. Given that there
are (conservatively) 100,000 PPIs (Venkatesan et al., 2009), our
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less, here is what we know so far.
Analyses of PPIs in which crystal structures are available for
both the protein-protein and protein-small-molecule reveal
someprovocative themes (JohnsonandKaranicolas, 2013;Smith
and Gestwicki, 2012; Wells and McClendon, 2007). First, PPI
target proteins tend to have extended binding grooves that may
be divided into three or more (visible) subpockets (Fuller et al.,
2009). Hot-spot residues are centered in or around these pockets
and are complementary on both sides of the interface. Second,
small conformational changes in thebinding site present a deeper
pocket to small molecules than to the partner protein. These
pockets are also more readily formed at the PPI interfaces than
elsewhere on the protein surfaces (Johnson and Karanicolas,
2013). The consensus is that ligand-binding surfaces (including
PPIs) haveahigherpropensity forbinding (tocognate ligands, sol-
vent molecules, inhibitors) than the rest of the protein surface.
Third, PPIs with small-molecule inhibitors tend to have small,
high-affinity interfaces and include a hot segment that can reca-
pitulate the binding of the partner protein. The observation that
high-affinity complexes havemore small-molecule ligands (Smith
andGestwicki, 2012) could imply that they are inherently ‘‘sticky.’’
Fortunately, however, there are many examples where peptides,
mutated proteins, and small molecules—such as bromodomain
inhibitors—bind to hot spot sites with higher affinities than the
native PPI. The preponderance of inhibitors for primary- and sec-
ondary-structural epitopes is probably due to their inherent
druggability, the fact that there are many such interfaces (Petsa-
laki and Russell, 2008), and the availability of design approaches.
In general, success seems to follow the simplicity of the epitopes
to mimic: primary is easier than secondary is easier than tertiary.
PPI inhibitors bind at the hot spot and tend tomimic the types of
binding interactions (e.g., hydrophobic)madeby thepartner.How-
ever, they generally use different functional groups and approach
thebinding site fromdifferent orientations than in thePPI. To reach
each subpocket in an extended interface, molecules often have
three distinct pharmacophores arrayed on a scaffold that serves
to orient them. Hence, orthosteric inhibitors have tended to be
larger than 500Da and to bemore 3D than the average compound
inanHTS library (Basseetal., 2013; Labbe´ etal., 2013). Toaddress
the potential lack of PPI-inhibitor-like compounds in HTS libraries,
investigators have proposed design of libraries that mimic the
shapes of current PPI inhibitors or protein secondary structures.
To date, more traction has been gained through virtual screening
and the use of nontraditional libraries, including larger, more natu-
ral-product-like macrocycles on the one hand and fragment-
based lead discovery on the other. Fragment screening has
been a particularly successful strategy, perhaps because the
pocket sizes at PPIs are close to fragment size and the bias in
chemical composition is lower. Experimental and virtual fragment
screens have even be used to define the druggability of a PPI (Haj-
duk and Greer, 2007; Kozakov et al., 2011).
On the other hand, second-generation clinical candidates are
generally smaller andmore efficient than their precursors, and so
perhaps the inherency of undruglikeness of PPI inhibitors has
been overstated (Table 1), particularly for small interfaces. Con-
cerns for LE and LLE originate from the observation that larger
molecules are more difficult to tune for in vivo properties. More
important than molecular weight per se is finding the balanceChemistry & Biology 2of hydrophobicity and electrostatics that provides tight, specific
binding to the protein target and acceptable pharmacokinetics
and pharmacodynamics. These issues are by no means specific
to PPI drug discovery.
Screening methodologies have also become more sophisti-
cated in the past 10 years. Foremost, there is an expanded
use of multiple drug discovery technologies, including an inte-
grated use of biochemistry, biophysics, structural biology, and
computational studies. Initial PPI inhibitors have been discov-
ered using a wide variety of methods; we conclude that the
screening format itself is less crucial than the compounds going
into the screen and the postscreening evaluation of hits. True
positives should be validated by demonstrating that the inhibitor
binds to a single site on the PPI target using biophysical and
structural methods. The importance of mechanism of action
over potency at the screening stage cannot be overstated.
What We Expect to See More of in the Near Future
Twenty years ago, PPIs were considered impossible fruit to
reach. Today, there are dozens of targets for which early stage
compounds have been discovered, and nearly a dozen com-
pounds have been in the clinic. Clearly, much progress has
been made, and this has generated the courage to move
forward, even with enthusiasm.
Ten years from now, how far will we have come? In terms of
methodology, new computational methods will allow better un-
derstanding of allostery and conformational ensembles that are
grist for improved virtual screening algorithms. There will be
a continued emphasis on fragment-based design, and also a
resurgence in natural products and natural-product-like mole-
cules, since biology has evolved these molecules for binding at
protein interfaces. Popular target classes will include epigenetic
and transcription factor complexes, signal transduction net-
works, and protein quality control systems, reflecting the need
for chemical tools to dissect these complex protein networks.
Building on the function of natural products, there will also be
greater emphasis on synthetic stabilizers of PPIs (Milroy et al.,
2014). Advances in cell biologywill allow faster discovery of com-
pounds’ mechanism of action and more translatable cell-based
assays. Importantly, the PPI inhibitors in clinical trials today will
be drugs benefitting patients. To us the writing is on the wall:
PPIs are a challenging but tractable class for small-molecule dis-
covery if the biology is compelling and the will is strong.
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